These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38617914)

  • 1. Design, synthesis, and evaluation of purine and pyrimidine-based
    Park SY; Gowda Saralamma VV; Nale SD; Kim CJ; Jo YS; Baig MH; Cho J
    Heliyon; 2024 Apr; 10(7):e28495. PubMed ID: 38617914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
    Li L; Liu J; Yang Z; Zhao H; Deng B; Ren Y; Mai R; Huang J; Chen J
    Eur J Med Chem; 2022 Apr; 233():114243. PubMed ID: 35276423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.
    Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F
    Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
    Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
    J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
    Bannoura SF; Khan HY; Azmi AS
    Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specific mutagenesis screening in KRAS
    Choi J; Shin JY; Kim TK; Kim K; Kim J; Jeon E; Park J; Han YD; Kim KA; Sim T; Kim HK; Kim HS
    Cancer Lett; 2024 Jun; 591():216904. PubMed ID: 38642608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
    Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
    Xiao X; Feng J; Ma J; Xia X; Liu X; Zhang J; Ding C; Pang X; Zhang A
    J Med Chem; 2023 Nov; 66(22):15524-15549. PubMed ID: 37921024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
    Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
    Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
    Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
    J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
    Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
    Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor efficacy of a potent and selective non-covalent KRAS
    Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
    Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.